Proteros Biostructures

Executive Summary

Proteros Biostructures is a Germany-based contract research organization (CRO) specializing in structure-based early-stage drug discovery. Founded in 1999 and headquartered in Martinsried, the company leverages a cutting-edge discovery engine that integrates protein science, X-ray crystallography, cryo-electron microscopy (cryo-EM), assay development, and biologics characterization. By enabling clients to tackle challenging targets, Proteros accelerates timelines from target identification to qualified hits. Despite operating in the competitive CRO space, its deep expertise in structural biology and biologics positions it as a partner of choice for pharma and biotech firms seeking to de-risk early-stage programs. The company remains privately held with no disclosed funding or valuation, but its longevity and technical breadth suggest a steady, self-sustaining business model focused on service revenue rather than proprietary pipelines.

Upcoming Catalysts (preview)

• Q4 2026Major Service Agreement with Top-Tier Pharma70% success
• Q1 2027Launch of New AI-Integrated Drug Discovery Platform50% success
• Q2 2026Expansion into High-Throughput Cryo-EM Services80% success